AlphaCentric Advisors’s Biogen BIIB Stock Holding History

AlphaCentric Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$703K	Buy	3,835 +208	+6%	+$38.3K	0.7%	35
2025 Q4	$638K	Buy	+3,627	New	+$593K	0.64%	44
2021 Q4	–	Sell	-400	Closed	-$113K	–	226
2021 Q3	$113K	Hold	400	–	–	0.03%	155
2021 Q2	$139K	Hold	400	–	–	0.04%	147
2021 Q1	$112K	Hold	400	–	–	0.04%	138
2020 Q4	$98K	Buy	400 +370	+1,233%	+$95.5K	0.04%	136
2020 Q3	$9K	Sell	30 -90	-75%	-$25.1K	﹤0.01%	158
2020 Q2	$32K	Buy	+120	New	+$36.1K	0.02%	103

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AlphaCentric Advisors's BIIB Position: Q1 2026 in Review

AlphaCentric Advisors increased its Biogen (BIIB) stake by 5.7% in Q1 2026, buying an estimated $38.3K and bringing the position to 3,835 shares worth $703K. The position accounts for 0.7% of the portfolio, ranked #35.

AlphaCentric Advisors first reported a position in BIIB in Q2 2020 and has held it in 8 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

AlphaCentric Advisors held 3,835 shares of Biogen worth $703K as of Q1 2026.
AlphaCentric Advisors bought 208 Biogen shares in Q1 2026, an estimated $38.3K.
Biogen made up 0.7% of AlphaCentric Advisors's portfolio in Q1 2026, its #35 holding.
AlphaCentric Advisors first reported a position in Biogen in Q2 2020 and has held it in 8 quarters since.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.